Showing results (111-120 of 135) with videos related to

Sort By:
Pageof 14
Inhalation Toxicology|September 20, 2008
Association of Inhalation Toxicologists (AIT) working party recommendation for standard delivered dose calculation and expression in non-clinical aerosol inhalation toxicology studies with pharmaceuticalsDavid J Alexander, Christopher J Collins, Derek W Coombs, et al.
Biorxiv : the Preprint Server for Biology|July 10, 2026
Cohesin residence time gates 3D genome response to histone hyperacetylationRebecca G Smith, Kathleen L Schiela, Hannah M Wilson, et al.
BMC Medical Education|March 1, 2013
Perceptions of UK medical graduates' preparedness for practice: a multi-centre qualitative study reflecting the importance of learning on the jobJan C Illing, Gill M Morrow, Charlotte R Rothwell nee Kergon, et al.
Molecular Cell|February 2, 2019
BRCA1 Haploinsufficiency Is Masked by RNF168-Mediated Chromatin UbiquitylationDali Zong, Salomé Adam, Yifan Wang, et al.
Molecular Cell|May 4, 2020
BRCA1 Mutational Complementation Induces Synthetic ViabilityJoseph Nacson, Daniela Di Marcantonio, Yifan Wang, et al.
Biorxiv : the Preprint Server for Biology|March 22, 2023
FAM122A ensures cell cycle interphase progression and checkpoint control as a SLiM-dependent substrate-competitive inhibitor to the B55⍺/PP2A phosphataseJason S Wasserman, Bulat Faezov, Kishan R Patel, et al.
Contemporary Clinical Trials|April 10, 2022
Defining optimal treatment for recurrent Clostridioides difficile infection (OpTION study): A randomized, double-blind comparison of three antibiotic regimens for patients with a first or second recurrenceStuart Johnson, Dale N Gerding, Xue Li, et al.
Molecular Cell|July 3, 2021
Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiencyKe Cong, Min Peng, Arne Nedergaard Kousholt, et al.
Nature Communications|July 9, 2024
FAM122A ensures cell cycle interphase progression and checkpoint control by inhibiting B55α/PP2A through helical motifsJason S Wasserman, Bulat Faezov, Kishan R Patel, et al.
Scientific Reports|June 28, 2018
Activation of the p53-MDM4 regulatory axis defines the anti-tumour response to PRMT5 inhibition through its role in regulating cellular splicingSarah V Gerhart, Wendy A Kellner, Christine Thompson, et al.
Pageof 14